Processa Pharmaceuticals, Inc.
February 11, 2025
Plymouth
Oncology

Processa Pharmaceuticals develops products that improve survival and quality of life for patients with unmet medical needs. Using our years of regulatory experience, we identify de-risked, underappreciated drugs and develop assets with an unmet medical need and leverage prior research toward high value clinical milestones and a lower risk of development failure.
Our portfolio of candidates is disease agnostic and all programs must meet strict evaluation criteria for further development including (but not limited to): representing an unmet medical need; have demonstrated (preferably in humans) clinical evidence of efficacy; that our Regulatory Science approach can make a difference in the time, cost and risk to obtaining marketing authorization and thus are highly capital efficient and contributes to substantial returns on equity.